Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaviscon for gastroesophageal reflux in preterm newborns
2008-001526-13Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of magnesium trisilicate in gastroesophageal reflux disease (GERD) and erosive esophagitis (EE) (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Efficacy on gastroesophageal reflux episodes and Safety during Gaviscon administration. Started Jun 2008; status: completed.
02
Drugs
magnesium trisilicate
03
Conditions
gastroesophageal reflux disease (GERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on 2008-001526-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001526-13.